Mechanisms and strategies to promote cardiac xenotransplantation

J Mol Cell Cardiol. 2022 Nov:172:109-119. doi: 10.1016/j.yjmcc.2022.07.013. Epub 2022 Aug 27.

Abstract

End stage heart failure is a terminal disease, and the only curative therapy is orthotopic heart transplantation. Due to limited organ availability, alternative strategies have received intense interest for treatment of patients with advanced heart failure. Recent studies using gene-edited porcine organs suggest that cardiac xenotransplantation may provide a future source of organs. In this review, we highlight the historical milestones for cardiac xenotransplantation and the gene editing strategies designed to overcome immunological barriers, which have culminated in a recent cardiac pig-to-human xenotransplant. We also discuss recent results of studies on the engineering of human-porcine chimeric organs that may provide an alternative and complementary strategy to overcome some of the major immunological barriers to producing a new source of transplantable organs.

Keywords: Cardiac xenotransplantation; ETV2; Gene editing; Heart failure; Immunosuppression; MYF5; MYF6; MYOD; Pig; Tolerance.

Publication types

  • Review
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Gene Editing
  • Heart Failure* / genetics
  • Heart Failure* / therapy
  • Heart Transplantation* / methods
  • Humans
  • Swine
  • Transplantation, Heterologous / adverse effects
  • Transplantation, Heterologous / methods
  • Transplants*